Lindbrook Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Lindbrook Capital’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,049	Closed	-$2.23K	–	2765
2023 Q3	$2.23K	Buy	+2,049	New	+$3.6K	﹤0.01%	2080

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Lindbrook Capital's LXRX Position: Q4 2023 in Review

Lindbrook Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2023, closing a stake of 2,049 shares — an estimated $2.23K sold.

Lindbrook Capital first reported a position in LXRX in Q3 2023 and held it in 1 quarter. The position peaked at $2.23K in Q3 2023. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2023.

Lindbrook Capital reported no remaining Lexicon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Lindbrook Capital sold 2,049 Lexicon Pharmaceuticals shares in Q4 2023, an estimated $2.23K.
Lindbrook Capital first reported a position in Lexicon Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Lindbrook Capital's Lexicon Pharmaceuticals position peaked at $2.23K in Q3 2023.
106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2023.

Based on Lindbrook Capital's 13F filing for Q4 2023, filed 1 Feb 2024.